“Lung Cancer Immunotherapy’s Initial Growth ‘Pseudoprogression’ Requires Multi-Factor Evaluation Beyond Imaging”

https://pubmed.ncbi.nlm.nih.gov/38112042

Immunotherapy for lung cancer can cause initial tumor growth – ‘pseudoprogression’ – before effective shrinkage, emphasizing the need for multi-factor evaluation beyond imaging alone.